نتایج جستجو برای: radioimmunotherapy

تعداد نتایج: 1230  

Journal: :Cancer research 2005
Xiao-Yan Zhao Doug Schneider Sandra L Biroc Renate Parry Bruno Alicke Pamela Toy Jian-Ai Xuan Choitsu Sakamoto Ken Wada Michael Schulze Beate Müller-Tiemann Gordon Parry Harald Dinter

Radiotherapy is an effective approach for the treatment of local prostate cancer. However, once prostate cancer metastasizes, radiotherapy cannot be used due to the distribution of multiple metastases to lymph nodes and bones. In contrast, radioimmunotherapy should still be efficacious in metastatic prostate cancer as radioisotopes are brought to tumor cells by targeting antibodies. Here we ide...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Adrienne H Brouwers Wilhelmina C A M Buijs Peter F A Mulders Pieter H M de Mulder Wim J M van den Broek Carola Mala Egbert Oosterwijk Otto C Boerman Frans H M Corstens Wim J G Oyen

PURPOSE A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequential high-dose treatments of radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell carcinoma. Here, we report the dosimetric analysis and the relationship between the development of a human antichimeric antibody response and altered pharmacokinetics. EXPERIMENTAL DESIGN Pa...

Iraj Nabipour Majid Assadi, Mohammad Ravanbod Shahram Amiri Shokrollah Farrokhi

The principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. This advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies (mAb). Radioactively-tagged antibodies which are applied in radioimmunotherapy (RIT), can target adjacen...

2014
Paul C Kruger David JL Joske

Aims: We evaluated the response and toxicity, after long-term follow up of Iodine-131 rituximab radioimmunotherapy in patients with follicular lymphoma under the routine clinical care of a single hematologist over a period of 12 years. Materials and methods: Patients received 131I-rituximab radioimmunotherapy according to a standard, personalized dosimetry protocol predicated upon a prescribed ...

Journal: :British journal of haematology 2014
Jonathan W Friedberg Joseph M Unger W Richard Burack Ajay K Gopal Robert N Raju Auayporn P Nademanee Mark S Kaminski Hongli Li Oliver W Press Thomas P Miller Richard I Fisher

Radiolabelled antiCD-20 antibodies have demonstrated single agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). The S0433 clinical trial enrolled patients with newly diagnosed, advanced stage or bulky stage II, histologically confirmed DLBCL. Patients received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two cycles of CHOP, then iodine-...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Karin Knogler Jürgen Grünberg Kurt Zimmermann Susan Cohrs Michael Honer Simon Ametamey Peter Altevogt Mina Fogel P August Schubiger Ilse Novak-Hofer

PURPOSE We examined the tumor-targeting and therapeutic effects of (67)Cu-labeled single amino acid mutant forms of anti-L1 monoclonal antibody chCE7 in nude mice with orthotopically implanted SKOV3ip human ovarian carcinoma cells. EXPERIMENTAL DESIGN For radioimmunotherapy, chCE7 antibodies with a mutation of histidine 310 to alanine (chCE7H310A) and a mutation of asparagine 297 to glutamine...

Journal: :Blood 2011
Ansgar S Schulz Gerhard Glatting Manfred Hoenig Catharina Schuetz Susanne A Gatz Simon Grewendorf Monika Sparber-Sauer Rainer Muche Norbert Blumstein Gabriele Kropshofer Meinolf Suttorp Donald Bunjes Klaus-Michael Debatin Sven N Reske Wilhelm Friedrich

Targeted irradiation of the bone marrow with radiolabeled monoclonal antibodies (radioimmunotherapy) represents a novel therapeutic approach with both myeloablative and antileukemic potential. In an open-label, single-center pilot study, 30 pediatric and adolescent patients undergoing hematopoietic cell transplantation for malignant (n = 16) and nonmalignant (n = 14) disorders received treatmen...

Journal: :Revista espanola de medicina nuclear 2006
C Emmanouilides

Radioimmunotherapy treatment for lymphoma is a novel targeted therapeutic approach. Several years of development of radioimmunotherapeutic compounds came to fruition in February of 2002 when 90Y-ibritumomab tiuxetan (Zevalin, Y2B8) was approved in the USA and later in Europe, for the treatment of relapsed or refractory, low grade or transformed B-cell lymphoma in the USA. 90Y-ibritumomab tiuxet...

2015
Wojciech Jurczak Elżbieta Kisiel Joanna Sawczuk-Chabin Piotr Centkowski Wanda Knopińska-Posłuszny Omeir Khan

AIM OF THE STUDY To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in the management of DLBCL. MATERIAL AND METHODS Patients with primary refractory or high-risk DLBCL (n = 18), ineligible for autologous stem-cell transplantation, were included in a retrospective study performed at three centers by the Polish Lymphoma Research Group (...

Journal: :Journal of Cancer Research and Therapeutics 2013

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید